chr19-32862207-C-CT
Position:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The ENST00000023064.9(SLC7A9):βc.614_615insAβ(p.Asn206GlufsTer3) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000515 in 1,613,766 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: π 0.00013 ( 0 hom., cov: 32)
Exomes π: 0.00055 ( 0 hom. )
Consequence
SLC7A9
ENST00000023064.9 frameshift
ENST00000023064.9 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 2.33
Genes affected
SLC7A9 (HGNC:11067): (solute carrier family 7 member 9) This gene encodes a protein that belongs to a family of light subunits of amino acid transporters. This protein plays a role in the high-affinity and sodium-independent transport of cystine and neutral and dibasic amino acids, and appears to function in the reabsorption of cystine in the kidney tubule. Mutations in this gene cause non-type I cystinuria, a disease that leads to cystine stones in the urinary system due to impaired transport of cystine and dibasic amino acids. Alternate transcript variants, which encode the same protein, have been found for this gene. [provided by RefSeq, Jul 2011]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 19-32862207-C-CT is Pathogenic according to our data. Variant chr19-32862207-C-CT is described in ClinVar as [Pathogenic]. Clinvar id is 288197.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SLC7A9 | NM_014270.5 | c.614_615insA | p.Asn206GlufsTer3 | frameshift_variant | 6/13 | ENST00000023064.9 | NP_055085.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SLC7A9 | ENST00000023064.9 | c.614_615insA | p.Asn206GlufsTer3 | frameshift_variant | 6/13 | 1 | NM_014270.5 | ENSP00000023064 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000138 AC: 21AN: 152182Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
21
AN:
152182
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000147 AC: 37AN: 251254Hom.: 0 AF XY: 0.000155 AC XY: 21AN XY: 135834
GnomAD3 exomes
AF:
AC:
37
AN:
251254
Hom.:
AF XY:
AC XY:
21
AN XY:
135834
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000555 AC: 811AN: 1461466Hom.: 0 Cov.: 33 AF XY: 0.000549 AC XY: 399AN XY: 727094
GnomAD4 exome
AF:
AC:
811
AN:
1461466
Hom.:
Cov.:
33
AF XY:
AC XY:
399
AN XY:
727094
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000131 AC: 20AN: 152300Hom.: 0 Cov.: 32 AF XY: 0.000148 AC XY: 11AN XY: 74472
GnomAD4 genome
AF:
AC:
20
AN:
152300
Hom.:
Cov.:
32
AF XY:
AC XY:
11
AN XY:
74472
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:11
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Cystinuria Pathogenic:6
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Nov 16, 2023 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Nov 01, 2002 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Sep 15, 2017 | The p.Asn206GlufsX3 (NM_014270.4 c.614dupA) variant in SLC7A9 (also referred to as c.799insA or c.800?801insA in the literature) has been reported in at least 2 5 heterozygotes, 2 homozygotes, and 2 compound heterozygotes with cystinuria (Le clerc 2002, Font-Llitjos 2005, Barbosa 2012, Rhodes 2015, and Halbritter 2015). Twenty one heterozygotes were noted to have non-type I cystinuria (heterozygotes with moderate to high excretion of cystine in urine and risk of forming urinary tract stones) (Font-Llitjos 2005, Barbosa 2012, Halbritter 2015). This variant has also been reported in ClinVar (Variation ID#288197), as pathogenic by two la boratories. It has been identified in 0.024% (30/126,648) of European chromosom es by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs745319034). This variant is predicted to cause a frameshift, which alte rs the protein?s amino acid sequence beginning at position 206 and leads to a pr emature termination codon 3 amino acids downstream. This alteration is then pred icted to lead to a truncated or absent protein. Loss of function of the SLC7A9 g ene is an established disease mechanism in cystinuria. Variants associated with non-type I cystinuria, such as this variant, are inherited in an autosomal domin ant manner with incomplete penetrance and cause more severe disease in the homoz ygous or compound heterozygous state. In summary, although additional studies a re required to fully establish its clinical significance, the p.Asn206GlufsX3 va riant is pathogenic for cystinuria in an autosomal dominant manner with incompl ete penetrance based on its occurrence in affected individuals and a predicted n ull effect. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Jun 30, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 28, 2017 | The SLC7A9 c.614dupA (p.Asn206GlufsTer3) variant, also referred to as c.799insA, has been reported in five studies in a total of 33 individuals with cystinuria, including three homozygotes, eight compound heterozygotes, and 22 heterozygotes with varying disease types (Leclerc et al. 2002; Font-Llitjos et al. 2005; Barbosa et al. 2012; Rhodes et al. 2015; Halbritter et al. 2015). Control data are unavailable for this variant, which is reported at a frequency of 0.00017 in the European (non-Finnish) population of the Exome Aggregation Consortium. The p.Asn206GlufsTer3 variant results in a frameshift, and is predicted to truncate the protein. While cystinuria generally displays an autosomal recessive mode of inheritance, some heterozygous carriers of variants in the SLC7A9 gene have abnormal urinary amino acid patterns and an increased risk of kidney stones (Eggermann et al. 2012). Based on the evidence and due to the potential impact of frameshift variants, the p.Asn206GlufsTer3 variant is classified as pathogenic for cystinuria. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Oct 08, 2024 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with cystinuria (MIM#220100). (I) 0108 - This gene is associated with both recessive and dominant disease. Some heterozygous variants have been reported to present with a milder phenotype (OMIM, PMID: 11157794). (I) 0112 - The condition associated with this gene has incomplete penetrance. Autosomal dominant cystinuria has been reported to have incomplete penetrance (PMID: 25964309). (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD <0.01 (v2: 41 heterozygotes, 0 homozygotes). (SP) 0701 - Other NMD-predicted variants comparable to the one identified in this case have very strong previous evidence for pathogenicity (DECIPHER). (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been classified as pathogenic by clinical laboratories (ClinVar), and has been observed as heterozygous, compound heterozygous and homozygous variants in multiple unrelated individuals with cystinuria (PMID: 12379955; 25964309; 28646536) (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jun 01, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 09, 2024 | Observed in multiple unrelated patients from different ethnic backgrounds with type II and type III cystinuria or with cystinuria and nephrolithiasis in published literature (PMID: 25296721, 12371955); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 12371955, 26990548, 25296721, 30609409, 29431110, 37279760, 28717662) - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 05, 2023 | This sequence change creates a premature translational stop signal (p.Asn206Glufs*3) in the SLC7A9 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC7A9 are known to be pathogenic (PMID: 11157794, 16838140, 25296721). This variant is present in population databases (rs745319034, gnomAD 0.02%). This premature translational stop signal has been observed in individual(s) with cystinuria in the heterozygous state (PMID: 12371955, 15635077, 16834950, 19782624, 21255007, 25109415, 25296721, 25964309). It has also been observed to segregate with disease in related individuals. This variant is also known as 799insA and c.800-801insA. ClinVar contains an entry for this variant (Variation ID: 288197). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Blueprint Genetics | Oct 16, 2018 | - - |
SLC7A9-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Nov 30, 2023 | The SLC7A9 c.614dupA variant is predicted to result in a frameshift and premature protein termination (p.Asn206Glufs*3). This common pathogenic SLC7A9 variant in the heterozygous state has been reported to cause moderate or severe cystinuria in different families, suggesting an autosomal dominant mode of inheritance (reported as 799insA at Leclerc et al. 2002. PubMed ID: 12371955). This variant has also been reported in the homozygous or compound heterozygous state in many unrelated individuals to cause cystinuria (Rhodes et al. 2015. PubMed ID: 25964309; Bisceglia et al. 2010. PubMed ID: 19782624; Barbosa et al. 2011. PubMed ID: 21255007). In summary, the c.614dup is classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at